OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
7-Point Dermoscopy ChecklistAJCC Melanoma Staging (8th Ed)ALDEN Algorithm (Drug Causality for SJS/TEN)BWH High-Risk SCC StagingBody Surface Area (BSA)Breslow Thickness and Clark LevelDLQIEASI ScoreMSK Melanoma NomogramMelanoma RiskPASI ScorePOEM (Patient-Oriented Eczema Measure)RegiSCAR Criteria for DRESSSCORADSCORTENmPASI (Modified PASI)

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • To objectively establish the probability that a specific medication caused Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
  • Superior to general adverse drug reaction scales (like Naranjo) due to strict timeline parameters specific to epidermal necrolysis.
CLINICAL INSIGHT

How it Works

Scoring Parameters

  • Delay to onset: (Time from initial drug intake to onset of index day). Peak causality is 5 to 28 days.
  • Probability of drug presence in the body on the index day.
  • Prechallenge & Rechallenge: Prior exposure to the drug with or without a reaction.
  • Dechallenge: Drug stopped and disease progression stops (less heavily weighted due to natural SJS/TEN progression).
  • Drug Notoriety: How often the drug is known to cause SJS/TEN (e.g., allopurinol, anti-epileptics).
  • Exclude other causes: Presence of infections or other highly notorious drugs.

Interpretation

  • < 0: Very unlikely
  • 0 - 1: Unlikely
  • 2 - 3: Possible
  • 4 - 5: Probable
  • ≥ 6: Very probable
CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

  • A medication started > 8 weeks prior to onset or < 4 days prior to onset is extremely unlikely to be the cause of SJS/TEN.
  • Always calculate an ALDEN score for every medication the patient is taking before discontinuing everything blindly, though stopping all non-essential medications immediately is standard.
CLINICAL INSIGHT

Next Steps

Next Steps

Permanently add any drug scoring ≥ 4 to the patient’s severe allergy list and notify family members, as there is a strong genetic HLA linkage for some SJS/TEN drugs (e.g., HLA-B*1502 and carbamazepine).

CLINICAL INSIGHT

Evidence Base

Primary Reference

SCORAD

SCORAD Index: Unified assessment of Atopic Dermatitis severity (Area, Intensity, Symptoms).
0%0%100%

erythema

edema

crusting

excoriation

lichenification

dryness

0010
0010
EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Evaluating the severity of atopic dermatitis (eczema) objectively.
  • Monitoring disease progression and treatment response over time.
  • Standardized reporting in clinical trials for atopic dermatitis therapies.
CLINICAL INSIGHT

How it Works

Formula

Variables

  • A: Extent of disease as percentage of Body Surface Area (BSA) affected (0-100).
  • B: Intensity of 6 specific morphologic lesions (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, and dryness/xerosis) graded 0-3. Max 18.
  • C: Subjective symptoms (pruritus and sleep loss) over the last 3 days, graded 0-10 on VAS. Max 20.
CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

  • Dryness (xerosis) is evaluated ONLY on uninvolved skin areas.
  • It combines both objective physician assessment and subjective patient-reported outcomes, making it very comprehensive.
  • A score > 50 indicates severe atopic dermatitis.
CLINICAL INSIGHT

Next Steps

Interpretation

  • < 25: Mild disease.
  • 25 - 50: Moderate disease.
  • > 50: Severe disease. Consider escalation to systemic immunosuppression or biologics.